8-K: Entera Bio Ltd. Files Opinion on ATM Share Issuance

Entera Bio Ltd. files an opinion regarding the issuance of up to 30,000,000 ordinary shares under its at-the-market (ATM) offering program.

Summary

• Entera Bio Ltd. has filed a Form 8-K solely to include Exhibit 5.1, an opinion from Israeli counsel Herzog Fox & Neeman.
• The opinion relates to the supplement to the prospectus regarding the offering and sale of up to 30,000,000 ordinary shares through an at-the-market (ATM) offering.
• These shares will be issued under a sales agreement with Leerink Partners LLC, formerly SVB Securities LLC.
• The shares are being offered pursuant to a registration statement filed with the SEC on May 27, 2022, and related prospectus supplements.
• The legal opinion confirms that upon payment of consideration, the ATM shares, when issued and sold under the Sales Agreement, will be duly authorized, validly issued, fully paid, and non-assessable.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. The filing is a procedural step related to a previously announced ATM offering, indicating the company is executing its capital-raising strategy. There are no explicit negative indicators.

Positives

• The legal opinion from Herzog Fox & Neeman supports the validity of the ATM share issuance, providing assurance to investors.
• The ATM offering provides Entera Bio with a mechanism to raise capital.

Risks

• The opinion assumes the Sales Agreement remains effective and legally binding on the Agent.
• The opinion assumes that the terms of the ATM Shares will not violate any applicable law or breach any agreement binding upon the Company.
• The opinion assumes that the Company will not issue or sell through the Agent such number of ATM Shares that exceeds the number of shares or dollar amount of Ordinary Shares registered on the Registration Statement.

Future Outlook

The company intends to issue the ATM Shares from time to time on a delayed or continuous basis.

Industry Context

ATM offerings are a common method for biotech companies to raise capital, particularly when seeking to fund ongoing research and development activities. This allows companies to sell shares into the market over time, potentially minimizing the impact on the stock price compared to a large, single offering.

Comparison to Industry Standards

• Many small-cap biotech companies, such as XOMA Corporation and Agenus Inc., utilize ATM offerings to raise capital.
• The size of the offering (up to 30,000,000 shares) is within the typical range for ATM offerings by companies of similar market capitalization.
• The legal opinion provided by Herzog Fox & Neeman is a standard requirement for such offerings, ensuring compliance with securities laws.

Stakeholder Impact

• Shareholders may experience dilution as a result of the new share issuance.
• The capital raised could benefit the company's operations and long-term growth.

Next Steps

• Entera Bio will continue to issue ATM shares over time.
• Herzog Fox & Neeman will review corporate approval documents prior to each issuance of ATM shares.

Key Dates